Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
The health insurer reported a stronger quarter driven by lower medical costs and momentum at Optum Insight, then increased its 2026 earnings and cash flow expectations.
THE APEX TIMES
THE APEX TIMES
UnitedHealth Group reported second-quarter results that beat Wall Street expectations and raised its full-year earnings outlook, sending the stock up roughly 5% in post-market trading on July 16, according to a market report.
THE APEX TIMES
A new equity research note highlighted continued progress in Johnson & Johnson’s Innovative Medicine segment, suggesting the company’s near-to-medium term product trajectory could extend into 2027.
THE APEX TIMES
Europe’s approval of an oral version of Wegovy gives Novo Nordisk another lead in the race against Eli Lilly’s weight-loss pipeline, according to reporting.
THE APEX TIMES
A market report says Eli Lilly is in talks about buying ATAI, sending ATAI’s stock sharply higher as investors wait for details on whether a deal is actually being structured.
THE APEX TIMES
The healthcare conglomerate said its second-quarter results came in above expectations and that strength in its Innovative Medicine segment, along with pipeline progress, supports an upward revision to its 2026 outlook.
THE APEX TIMES
A July 16 market note on UnitedHealth’s second-quarter results urged investors to look beyond headline profit and revenue, focusing instead on metrics analysts typically use to gauge medical cost pressure, utilization and operating efficiency.
THE APEX TIMES
A broad pullback in chip-related names, including Micron, has renewed questions on how long the AI spending surge can last. UnitedHealth is among the large stocks highlighted as markets sort through what comes next.
THE APEX TIMES
The announcement lifted AtaiBeckley shares by more than 30% on Thursday, as the companies positioned the acquisition around expanding Lilly’s neuroscience development efforts.
